Equities analysts expect MedEquities Realty Trust Inc (NYSE:MRT) to announce $0.30 earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for MedEquities Realty Trust’s earnings, with the highest EPS estimate coming in at $0.31 and the lowest estimate coming in at $0.29. MedEquities Realty Trust reported earnings per share of $0.27 in the same quarter last year, which indicates a positive year over year growth rate of 11.1%. The business is scheduled to announce its next quarterly earnings results on Tuesday, August 14th.
According to Zacks, analysts expect that MedEquities Realty Trust will report full-year earnings of $1.20 per share for the current financial year, with EPS estimates ranging from $1.19 to $1.22. For the next fiscal year, analysts expect that the company will report earnings of $1.25 per share, with EPS estimates ranging from $1.22 to $1.27. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover MedEquities Realty Trust.
Get MedEquities Realty Trust alerts:MedEquities Realty Trust (NYSE:MRT) last announced its quarterly earnings results on Thursday, May 10th. The financial services provider reported $0.16 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.30 by ($0.14). MedEquities Realty Trust had a net margin of 34.63% and a return on equity of 6.17%. The company had revenue of $16.72 million for the quarter, compared to the consensus estimate of $16.41 million.
MRT has been the topic of several analyst reports. KeyCorp decreased their price target on MedEquities Realty Trust from $13.00 to $12.00 and set an “overweight” rating on the stock in a research report on Monday, April 16th. ValuEngine lowered MedEquities Realty Trust from a “buy” rating to a “hold” rating in a report on Friday, February 23rd. Citigroup cut their price objective on MedEquities Realty Trust from $12.00 to $10.00 and set a “neutral” rating for the company in a report on Thursday, March 1st. B. Riley set a $13.00 price objective on MedEquities Realty Trust and gave the stock a “buy” rating in a report on Thursday, February 22nd. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $11.00 price objective (down previously from $12.00) on shares of MedEquities Realty Trust in a report on Wednesday, May 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $12.25.
Shares of MRT traded down $0.01 during midday trading on Friday, hitting $10.59. 398,600 shares of the company traded hands, compared to its average volume of 155,375. MedEquities Realty Trust has a one year low of $9.67 and a one year high of $13.06. The stock has a market cap of $343.74 million, a PE ratio of 9.29 and a beta of -0.12.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 5th. Stockholders of record on Tuesday, May 22nd were issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 7.93%. The ex-dividend date of this dividend was Monday, May 21st. MedEquities Realty Trust’s payout ratio is 73.68%.
In other news, Director Bluemountain Capital Managemen sold 17,674 shares of the business’s stock in a transaction dated Friday, May 4th. The stock was sold at an average price of $10.16, for a total transaction of $179,567.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 363,688 shares of company stock valued at $3,756,271 in the last three months. 2.50% of the stock is owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. LSV Asset Management purchased a new stake in MedEquities Realty Trust in the fourth quarter worth approximately $103,000. MetLife Investment Advisors LLC purchased a new stake in MedEquities Realty Trust in the fourth quarter worth approximately $120,000. Barclays PLC boosted its stake in MedEquities Realty Trust by 252.2% in the first quarter. Barclays PLC now owns 16,016 shares of the financial services provider’s stock worth $168,000 after buying an additional 11,469 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in MedEquities Realty Trust by 221.9% in the first quarter. JPMorgan Chase & Co. now owns 19,898 shares of the financial services provider’s stock worth $210,000 after buying an additional 13,717 shares in the last quarter. Finally, UBS Group AG boosted its stake in MedEquities Realty Trust by 52.3% in the first quarter. UBS Group AG now owns 23,234 shares of the financial services provider’s stock worth $244,000 after buying an additional 7,978 shares in the last quarter. 93.53% of the stock is owned by institutional investors and hedge funds.
MedEquities Realty Trust Company Profile
MedEquities Realty Trust (NYSE: MRT) is a self-managed and self-administered real estate investment trust that invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company's management team has extensive industry experience in acquiring, owning, developing, financing, operating, leasing and monetizing many types of healthcare properties and portfolios.
Get a free copy of the Zacks research report on MedEquities Realty Trust (MRT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment